Xepenta-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Pantoprazole 40mg, designed for the effective management of gastrointestinal disorders. Domperidone, a dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, bloating, and discomfort associated with delayed gastric emptying and gastroparesis. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing symptomatic relief from acid-related conditions including gastroesophageal reflux disease (GERD), erosive esophagitis, and Zollinger-Ellison syndrome. The synergistic action of these two agents in Xepenta-DSR Capsule addresses both motility and acid secretion abnormalities, offering comprehensive treatment for patients with upper gastrointestinal symptoms. It is indicated for use in adults with conditions such as GERD accompanied by delayed gastric emptying or functional dyspepsia. Administration should follow medical advice, considering contraindications such as known hypersensitivity to the components, and caution is advised in patients with cardiac arrhythmias or hepatic impairment. Adverse effects may include headache, dry mouth, abdominal cramps, and, rarely, extrapyramidal symptoms. Xepenta-DSR Capsule should be used under strict medical supervision to ensure efficacy and safety.